Tumor studies confirmed the superior immunogenicity and tumor control of the APC-targeted DNA vaccine, with CCL19 initiating an earlier immune response and enhancing anti-tumor effectiveness.<h4>Conclusions</h4>CCL19 serves as an effective APC-targeting unit when fused to neoantigens, maintaining chemotactic and signaling properties that improve DNA vaccine immunogenicity and tumor control. Here, CCL19 is linked to neoplasm.